Aprea Therapeutics Secures $30M Oversubscribed Financing to Accelerate WEE1 Inhibitor Trial
Aprea Therapeutics closed a $30 million oversubscribed private placement led by Soleus Capital, issuing warrants exercisable at $0.683 per share through December 31, 2029. Net proceeds will fund general corporate purposes and expand the ACESOT-1051 trial to enroll 50 patients with uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer.
1. Private Placement Details
Aprea Therapeutics completed an oversubscribed private placement on March 31, raising gross proceeds of $30 million. The financing was led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management, existing investors, and company insiders.
2. Use of Proceeds for APR-1051
Net proceeds will support general corporate purposes and research and development, with a primary focus on accelerating the ACESOT-1051 trial. The company plans to enroll at least 50 patients with uterine serous carcinoma and cyclin E-overexpressing, platinum-resistant ovarian cancer to refine its biomarker-driven strategy.
3. Warrant Structure and Expiry
The company issued pre-funded warrants permitting the purchase of approximately 37.2 million common shares and an equal number of standard warrants at an exercise price of $0.683 per share. All warrants are exercisable immediately and expire on December 31, 2029, supporting potential future capital upon exercise.